The Genetic Basis of Future Pharmacological Strategies for the Management of Comorbid Obesity and Depression: A Scoping Review

Depression and obesity are highly comorbid with one another, evidence of bidirectional causal links between each disorder a shared biological basis. Genetic factors play major role in influencing both the occurrence depression obesity, their courses, response to existing treatments. The current paper is scoping review studies that have evaluated contribution specific genetic variants comorbidity depression. Based on search PubMed EMBASE databases, 28 were included this review, covering 54 candidate genes. Positive associations identified for 14 loci (AKR1C2, APOA5, COMT, DAT1, FTO, KCNE1, MAOA, MC4R, MCHR2, NPY2R, NR3C1, Ob, PCSK9, TAL1). Replicated findings across two or more independent samples observed FTO MC4R Many these gene products represent novel molecular targets pharmacological management interact other not pharmacologically influenced by anti-obesity antidepressant medications. implications future drug development discussed, an emphasis recent polygenic architecture precision-medicine approach conditions.